Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2-Reference-Cited by-同舟云学术

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2

Published:2014-04 Issue:4 Volume:25 Page:808-815
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Rugo H.S.,Pritchard K.I.,Gnant M.,Noguchi S.,Piccart M.,Hortobagyi G.,Baselga J.,Perez A.,Geberth M.,Csoszi T.,Chouinard E.,Srimuninnimit V.,Puttawibul P.,Eakle J.,Feng W.,Bauly H.,El-Hashimy M.,Taran T.,Burris H.A.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/25/4/808/16703289/mdu009.pdf

Reference19 articles.

1. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Breast Cancer. Version 2.2013. www.nccn.com (5 July 2013, date last accessed)

2. 1st International consensus guidelines for advanced breast cancer (ABC 1);Cardoso;Breast,2012

3. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer;Baselga;N Engl J Med,2012

4. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer;Miller;J Clin Invest,2010

5. Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling;Beeram;Ann Oncol,2007

Cited by 113 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dexamethasone to prevent everolimus-induced stomatitis (Alliance MIST Trial: A221701);Seminars in Oncology;2023-02

2. Safety of Sirolimus in Patients with Tuberous Sclerosis Complex under Two Years of Age—A Bicenter Retrospective Study;Journal of Clinical Medicine;2023-01-03

3. A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE);ESMO Open;2022-12

4. Oral Oncolytics: Using Remote Technology to Improve Access, Operational Efficiency, and Satisfaction;Clinical Journal of Oncology Nursing;2022-06-01

5. Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the treatment of advanced breast cancer;Cancer Innovation;2022-06